US 8404711
5-HT4 receptor agonist compounds for treatment of cognitive disorders
granted A61KA61K31/445A61K31/454
Quick answer
US patent 8404711 (5-HT4 receptor agonist compounds for treatment of cognitive disorders) held by Theravance, Inc. expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/445, A61K31/454, A61K31/4545, A61K31/46